Literature DB >> 20392404

Drug resistance pattern in multidrug resistance pulmonary tuberculosis patients.

Nisar Ahmed Rao1, Muhammad Irfan, Mir Mir Soomro, Zeeshan Mehfooz.   

Abstract

OBJECTIVE: To evaluate the frequency of drug resistance profiles of multidrug resistant tuberculosis (MDR-TB) isolates of pulmonary tuberculosis patients, against both the first and the second line drugs. STUDY
DESIGN: An observational study. PLACE AND DURATION OF STUDY: The multidrug resistant tuberculosis (MDR-TB) ward of Ojha Institute of Chest Diseases (OICD), Karachi, from 1996 to 2006.
METHODOLOGY: Culture proven MDR-TB cases (resistant to both isoniazid and Rifampicin) were retrospectively reviewed. Susceptibility testing was performed at the clinical laboratory of the Aga Khan University. Sensitivity against both first and second line anti-tuberculosis drugs was done. Susceptibility testing was performed using Agar proportion method on enriched middle brook 7H10 medium (BBL) for Rifampicin, Isoniazid, Streptomycin, Ethambutol, Ethionamide, Capreomycin and Ciprofloxacin. Pyrazinamide sensitivity was carried out using the BACTEC 7H12 medium. During the study period MTB H37Rv was used as control.
RESULTS: Out of total 577 patients, all were resistant to both Rifampicin and Isoniazid (INH). 56.5% isolates were resistant to all five first line drugs. Resistances against other first line drugs was 76.60% for Pyrazinamide, 73% for Ethambutol and 68.11% for Streptomycin. Five hundred and ten (88%) cases were MDR plus resistant to one more first line drug. Forty (07%) isolates were MDR plus Quinolone-resistant. They were sensitive to Capreomycin but sensitivity against Amikacin and Kanamycin were not tested.
CONCLUSION: There were high resistance rates in MDR-TB to remaining first line and second line drugs. Continuous monitoring of drug resistance pattern especially of MDR isolates and treatment in specialized centers is a crucial need for future TB control in Pakistan.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20392404     DOI: 04.2010/JCPSP.262265

Source DB:  PubMed          Journal:  J Coll Physicians Surg Pak        ISSN: 1022-386X            Impact factor:   0.711


  5 in total

Review 1.  Second line drug susceptibility testing to inform the treatment of rifampin-resistant tuberculosis: a quantitative perspective.

Authors:  Emily A Kendall; Ted Cohen; Carole D Mitnick; David W Dowdy
Journal:  Int J Infect Dis       Date:  2016-12-19       Impact factor: 3.623

Review 2.  'Z(S)-MDR-TB' versus 'Z(R)-MDR-TB': improving treatment of MDR-TB by identifying pyrazinamide susceptibility.

Authors:  Ying Zhang; Kwok Chiu Chang; Chi-Chiu Leung; Wing Wai Yew; Brigitte Gicquel; Dorothy Fallows; Gilla Kaplan; Richard E Chaisson; Wenhong Zhang
Journal:  Emerg Microbes Infect       Date:  2012-07-25       Impact factor: 7.163

3.  Expected effects of adopting a 9 month regimen for multidrug-resistant tuberculosis: a population modelling analysis.

Authors:  Emily A Kendall; Anthony T Fojo; David W Dowdy
Journal:  Lancet Respir Med       Date:  2016-12-16       Impact factor: 30.700

4.  The burden of pre-extensively and extensively drug-resistant tuberculosis among MDR-TB patients in the Amhara region, Ethiopia.

Authors:  Agumas Shibabaw; Baye Gelaw; Wondwossen Gebreyes; Richard Robinson; Shu-Hua Wang; Belay Tessema
Journal:  PLoS One       Date:  2020-02-13       Impact factor: 3.240

5.  Resistance patterns, prevalence, and predictors of fluoroquinolones resistance in multidrug resistant tuberculosis patients.

Authors:  Nafees Ahmad; Arshad Javaid; Syed Azhar Syed Sulaiman; Long Chiau Ming; Izaz Ahmad; Amer Hayat Khan
Journal:  Braz J Infect Dis       Date:  2015-11-25       Impact factor: 3.257

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.